Search Back New search Go to resultsDiseaseMain groupSolid TumorsProtocol groupGastroenterologic OncologyGynecological OncologyHead and Neck OncologyNeuro-OncologyThoracic TumorsTumor, regardless of entityDiseaseBile Duct CarcinomaOvarian TumorPancreatic CancerTumor Biomarker DefinedSubgroupBRAF V600-MutationHER2+ICD10C24.-C24.0C24.1C24.8C24.9C25.-C56MeSHBile Duct NeoplasmsBiliary TractBiliary Tract NeoplasmsCommon Bile Duct NeoplasmsNeoplasmsPancreatic NeoplasmsSequenceChemotherapyChemo-substanceDabrafenibTrametinibTrastuzumab emtansineChemo-substanceDabrafenibTrametinibTrastuzumab emtansineChemo-substanceDabrafenibTrametinibTrastuzumab emtansineChemo-substanceDabrafenibTrametinibTrastuzumab emtansineNo. Substances12 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronSupportive substanceBalanced Crystalloid SolutionGranisetronNo. Substances2Protocol classificationTherapy classificationalternativeIntensityStandard doseTherapy indicationSecond lineseveral possibleTherapy phaseTherapy intentionpalliativeRisksAnemia Hb below 8g/dlAstheniaCardiotoxicityDiarrheaEmetogenicity (ASCO)Emetogenicity (MASCC/ESMO)Febrile NeutropeniaHeadacheHepatotoxicityHyponatremiaIncrease Alkaline PhosphataseIncrease AminotransferasesNeuropathyNeutropeniaPyrexiaRashThrombocytopenia below 50 000/µl only studiesPublicationAuthorJhaveri KLSalama AKSDiseaseLokal fortgeschrittene oder metastasierte Karzinome, BRAF V600E mutiert, Progress nach der Erstlinientherapie, ECOG 0-2Solide Tumoren HER2 amplifiziert, außer Mamma-Ca oder AEG-Tumoren und Magen-Ca, ECOG 0-1OriginDuke University, Durham, NC, NCI-MATCH Trial Subprotocol HMemorial Sloan-Kettering Center, New York, USA, NCI-MATCH trial (EAY131)Protocols in Revision 2 protocols foundProtocols under revision.Dabrafenib 150 / Trametinib 2, Tumor Biomarker Defined (PID2197 V1.0)Trastuzumab Emtansine 3.6, Tumor Biomarker Defined (PID1677 V1.0)
